SPAP prolonged until the end of 2027

We are pleased to announce that, on the initiative of SSMO, all current partner companies have agreed to an prolongation of the Swiss Patient Access Program (SPAP). This important program […]

SSMO statement on Lunsumio

The SSMO takes note of this unprecedented incident with concern. Although follicular lymphoma is a relatively rare form of cancer affecting relatively few patients, it nevertheless raises an important question: […]

SOHC 2025

19 – 21 November 2025 Congress Center Basel “Bridging the gaps in patient care” The SOHC is a unique opportunity to meet for personal interaction and a joint learning experience […]

DGHO Jahrestagung 2025 in Köln

Die Planung des Kongresses schreitet voran und die ersten Meilensteine sind erreicht. Freuen Sie sich auf gute Vorträge, innovative Formate und den Austausch mit Expert:innen. Vorprogramm online  Erste Einblicke in […]

SPAP – A contribution to alleviating hardship cases according to Article 71a-d KVV

Access to medication and reimbursement of so-called individual case assessments (Art. 71 a-d KVV) for chronic and fatal illnesses is unique in Switzerland. Nevertheless, patients repeatedly fall through the cracks […]

Third pharmaceutical company at SPAP

On 1 January 2025, iQone will become the third pharmaceutical company to join the Swiss Patient Access Program (SPAP). So far, Roche and AstraZeneca are partner companies of SPAP. As […]

Current status of SPAP – Swiss Patient Access Program

Current status of the SPAP project (Swiss Patient Access Program): The project has now been running for a little over a year The processes have been thoroughly tested and are […]

SGMO Curriculum – the new continuous education series in medical oncology

The SSMO, together with its cooperation partners, the Forum for Medical Education (FOMF) and the Swiss Academy of Medical Oncology (SAMO), offers a structured, application-oriented training programme for oncologists who […]

KVV/KLV revision – implementation difficulties: statement to the FDIA

The following letter was sent today (16 September 2024) to the FDIA by SSMO, SSH, SPOG, SAKK, the Swiss Cancer League, unimedsuisse and kosek: Herausforderungen bei der Anwendung von Artikel […]

OHI/OHCS revision – practical implications for doctors

On 1 January 2024, a comprehensive revision of the Ordinance on Health Insurance (OHI) and the FDHA Ordinance on Health Care Services (OHCS) came into force. On behalf of the […]